During the past decade, Randy Scharlach, MD conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Randy Scharlach, MD" are "Breakthrough Cancer Pain" (1 trials), "Breast Cancer With Low to Intermediate HER2 Expression" (1 trials) and "Quality of Life" (1 trials). Many other conditions were trialed in "Randy Scharlach, MD" in a lesser frequency.

Most popular intervention types in "Randy Scharlach, MD" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Fentanyl" (1 trials), "Leukine® (sargramostim, GM-CSF) and water for injection" (1 trials) and "NeuVax™ vaccine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Randy Scharlach, MD" are 1 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Randy Scharlach, MD". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Randy Scharlach, MD, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Randy Scharlach, MD, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".